Since the activity of SUMOylation regulators is closely associated with global SUMOylation levels, we performed IHC for SUMO1 and SUMO2/3 on FFPE tissue sections from ovarian cancer patients at different stages. The gene discussed is SUMO2; the disease is ovarian cancer.